Akademik Veri Yönetim Sistemi
Cumhuriyet Dental Journal, cilt.28, sa.1, ss.9-20, 2025 (Scopus)
Objectives: Similar mechanisms and risk factors are thought to contribute to the progression of both osteoporosis and periodontitis. Bisphosphonates (BPs) exhibit anti-inflammatory effects and inhibit the release of proinflammatory cytokines, making them a potential adjunctive therapy in periodontal treatment. This study aimed to evaluate the impact of medical treatment for osteoporosis with BPs and non-surgical periodontal therapy on salivary levels of interleukin-1 beta (IL-1β), interleukin-17 (IL-17), and 8-Hydroxy-deoxyguanosine (8-OHdG), as well as on clinical outcomes. Materials and Methods: Three groups of 75 participants were assigned based on their systemic and periodontal health. Group 1 included 25 postmenopausal women with both osteoporosis and periodontitis. Group 2 consisted of 25 systemically healthy women with periodontitis, while Group 3 comprised 25 women who were both systemically and periodontally healthy. Patients who used systemic alendronate once weekly (70 mg) for at least 3 months were included. Baseline and 1- and 3-month after periodontal therapy plaque index (PI), gingival index (GI), probing depth(PD), bleeding on probing(BOP), and clinical attachment levels (CAL) were assessed. The enzyme-linked immunosorbent assay (ELISA) was used to measure the levels of IL-1β, IL-17, and 8-OHdG in salivary samples. Results: The clinical parameters, including GI, PD, and CAL, were significantly higher in osteoporotic patients (p < 0.05). After periodontal therapy, Groups 1 and 2 demonstrated significant reductions in clinical parameters (PI, PD, BOP, and CAL) at the 3-month follow-up compared to baseline values (p < 0.05). In periodontitis groups, the mean IL-1β, IL-17, and 8-OHdG levels were found to be significantly higher (p<0.001). 1- and 3-month comparisons revealed significant reductions in IL-1β, IL-17, and 8- OHdG than the baseline values in periodontitis groups (p<0.05). In the patients with osteoporosis (group 1), baseline 8-OHdG levels were significantly greater (p<0.001). No significant differences regarding clinical measurements and biomarkers between the periodontitis groups were found following the initial phase of periodontal therapy. Conclusions: Osteoporosis patients diagnosed with periodontitis and taking BPs exhibited elevated levels of the oxidative stress biomarker 8-OHdG compared to other patients. Salivary biomarkers and periodontal parameters responded similarly to initial periodontal therapy in patients receiving BPs. In the short term, taking oral BP medication did not significantly impact clinical parameters or salivary biomarkers.